Myelodysplastic Syndrome Immunotherapy
Study data from Cornell University, Center for Lymphoma and Myeloma update knowledge of myelodysplastic syndrome immunotherapy
Published in Blood Weekly, August 23rd, 2007
Researchers detail in "Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma," new data in myelodysplastic syndrome. "Patients with indolent non-Hodgkin lymphoma (I-NHL) often receive multiple courses of cytotoxic chemotherapy over several years. Radioimmunotherapy (RIT) has become an important part of treatment for relapsed patients and tositumomab/lodine I-131 tositumomab is a promising regimen currently being incorporated into first-line therapy," investigators in the United States report.
"While treatment-related myelodysplasia (tMDS) and acute...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-08-23)
More Articles from Blood Weekly
- Battery Technology
Miniature Implanted Devices Could Treat Epilepsy, Glaucoma - Bioengineering
Lab Receives Grant to Prepare Artificial Lung for Clinical Trial - Biomedicine
Electrical implant steadies balance disorder in animals - Biomedicine
Study Determines That Benchmarks for Clinical Engineering Activities Are Beneficial - Bioterrorism
UC San Diego Fighting Terrorism on the Medical Front - Blood Safety
Improving blood safety worldwide - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
